Modality
mAb
MOA
GLP-1ag
Target
SOS1
Pathway
Cell Cycle
MDDDMD
Development Pipeline
Preclinical
~Apr 2021
→ ~Jul 2022
Phase 1
Oct 2022
→ May 2028
Phase 1Current
NCT04447534
1,867 pts·DMD
2022-10→2028-05·Completed
1,867 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-032.1y awayPh2 Data· DMD
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Complet…
Catalysts
Ph2 Data
2028-05-03 · 2.1y away
DMD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04447534 | Phase 1/2 | DMD | Completed | 1867 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 |